This bill asks the government's top auditor (the Comptroller General) to investigate how prescription drug prices are being used to calculate payments throughout the drug supply chain. Right now, many middlemen in the prescription drug system—like pharmacy benefit managers, drug wholesalers, and pharmacies—charge fees that are based on the price of the drug itself. For example, someone might take a percentage of the drug's price as their fee. The bill wants to understand exactly how widespread this practice is, how much money is involved, and whether it creates problems.

The study will look at all the different players involved in getting drugs from manufacturers to patients—including insurance companies, pharmacies, wholesalers, and various advisors and consultants. It will examine whether companies that own each other charge different fees than companies that don't have that relationship, and whether these price-based fee structures might encourage people to push more expensive drugs over cheaper alternatives (even when the cheaper drug works just as well). The government auditor will have two years to complete this investigation and report back to Congress with findings and recommendations for any new laws or rule changes that might be needed.

Basically, this is about transparency and making sure that the way middlemen make money isn't accidentally driving up drug prices for patients and taxpayers. The bill doesn't change any rules itself—it just orders an investigation to see if there's a problem that needs fixing.